Zbrozek, Arthur S <br/><br/>
Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.  [electronic resource] 

 -  PharmacoEconomics  2010 
 - 577-84 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1179-2027 
<br/><br/><label>Standard No.: </label>10.2165/11535290-000000000-00000  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carcinoma, Renal Cell--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Interferon Type I--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Quality-Adjusted Life Years<br/>Recombinant Proteins<br/>Sirolimus--administration & dosage<br/>Surveys and Questionnaires<br/>Young Adult